- |||||||||| APH1105 / Aphios
Review, Journal: Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications. (Pubmed Central) - May 27, 2023
Currently, no drugs for intranasal administration in ATD have marketing approval, with only three candidates, insulin, rivastigmine and APH-1105, being clinically investigated. Further studies with different candidates will eventually confirm the potential of the intranasal route of administration in the treatment of ATD.
- |||||||||| APH1105 / Aphios
Trial completion date, Trial primary completion date: Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) - Aug 18, 2021
P2, N=60, Not yet recruiting,
Further studies with different candidates will eventually confirm the potential of the intranasal route of administration in the treatment of ATD. Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Sep 2024
|
